Pacific Biosciences Of California Stock News

Investors are trying to get on an even keel after a rough start to 2022.

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus BioAtla, Bristol-Myers Squibb Announce Collaboration To Evaluate ADC-Opdivo Combo In Solid Tumors BioA

Huadi International Group (HUDI) -16%.Bone Biologics (BBLG) -12%.Reviva Pharmaceuticals (RVPH) -10%.Pacific Biosciences of California PACB -9% after reports lower than expected prelim

Preliminary fourth-quarter results reached a record high but didn't quite meet expectations.

New collaboration builds on existing relationship between the two companies to develop desktop systems for the clinical market in China

Pilot project designed to demonstrate the power of HiFi sequencing to effectively and efficiently identify novel variants following short-read genome sequencing Pilot project designed to demonstrate t

MENLO PARK, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB ), a leading provider of high-quality, highly accurate sequencing platforms, today announced a collaboration with Genomics England to study PacBio''s technology for identifying genetic variants in unexplained rare disease cases. Genomics England was initially created to deliver the 100,000 Genomes Project the largest whole genome sequencing disease cohort of cancer and rare disease participants in the National Health Service (NHS). The study will re-sequence a selection of samples collected during Genomics England''s 100,000 Genomes Project, which were previously analyzed with short read sequencing technology. The study is intended to reveal potential operational and clinical benefits of long-read sequencing in identifying genetic mutations associated with rare diseases. "PacBio HiFi sequencing is a powerful tool for understanding the genetic underpinnings of rare disease, cancer, and other applications as it provides clinical researchers with the ability to view the genome more completely than other sequencing technologies," said Christian Henry, President and Chief Executive Officer of PacBio. "Our collaboration with Genomics England is part of a broader strategy to demonstrate the benefits of HiFi sequencing when attempting to identify rare diseases, and follows recent announcements of rare disease-focused research collaborations with Radboud University Medical Center ,

Initial proof-of-concept work suggests strong potential to further improve PacBio’s highly accurate HiFi Sequencing with Google deep learning technologies Initial proof-of-concept work suggests stro

MENLO PARK, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing platforms, today announced unaudited preliminary revenue

PacBio's (PACB) sequencing system enhances Radboudumc's SMRT sequencing capability through the addition of two new PacBio Sequel IIe systems.

Added whole genome sequencing capacity enables the SOLVE-RD research program to significantly increase sample throughput Added whole genome sequencing capacity enables the SOLVE-RD research program to

PacBio's (PACB) recent partnership with Care4Rare, with regard to a study, has the potential to enhance rare disease diagnosis within Canada.

The study will evaluate the impact of high-resolution genomes generated on PacBio technology in studying unsolved rare disease cases The study will evaluate the impact of high-resolution genomes gener

MENLO PARK, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- PacBio announced today that its executives will be speaking virtually at the following investor conference:

MENLO PARK, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- PacBio announced today that its executives will be speaking virtually at the following investor conference: